Medical Crossfire: How Should We Leverage Multidisciplinary Lung Cancer Care Teams in Managing Earlier Forms of NSCLC... When the Goal is Cure?

Register Now

October 24, 2022 from 6:30-8:30pm CST

Overview:

The development and clinical success of immune checkpoint inhibitor therapy in recent years has led to a paradigm shift in the treatment of lung cancer. The use of immune checkpoint inhibitors in earlier, stage I-III, potentially curable NSCLC holds significant potential and will rely upon defining biomarkers, investigating immunotherapy-based combinations, and administering immunotherapy as induction therapy.

This educational activity is an ancillary satellite educational symposium to the 2022 ASTRO Annual Meeting. The program brings together renowned experts across multiple disciplines in thoracic oncology in a PER Medical Crossfire^® educational format. The program will incorporate the latest data related to immune checkpoint inhibition strategies and clinical trial achievements into a discussion of real-world cases. Multidisciplinary discussion will focus on optimizing outcomes among patients with early-stage lung cancer.

Benefits of Attending:

• Recognize and manage immune-related adverse events with checkpoint inhibitor therapy
• Optimize outcomes for your patients with early-stage lung cancer
• Investigate immunotherapy-based combinations with the experts
• Consider recent clinical trial evidence in the context of real-world patient cases

Target audience: 

This educational program is directed toward medical, surgical and radiation oncologists who treat or manage patients with non-small cell lung cancer. Nurse practitioners, nurses, physician assistants, pharmacists, researchers, and other health care professionals interested in the treatment of non-small cell lung cancer are also invited to participate.

Learning objectives:

Upon completion of this activity, participants will be able to:

• Discuss the rationale for applying immunotherapeutic strategies to early-stage and locally advanced NSCLC settings, as well as key considerations in multidisciplinary coordination between thoracic surgeons, medical oncologists, and radiation oncologists
• Assess recent data and emerging trends utilizing immune checkpoint inhibitor-based strategies for the management of patients with unresectable stage III NSCLC
• Devise personalized care strategies to integrate evidence with evolving immunotherapy-based approaches to manage patients with resectable stage I-III NSCLC
• Create interdisciplinary care strategies for the management of stage I-III NSCLC that include methods to monitor for, identify, and mitigate the impact of irAEs

Faculty, Staff, and Planners’ Disclosures

The staff of Physicians’ Education Resource®, LLC, have no relevant financial relationships with ineligible companies.

PER® mitigated all COI for faculty, staff, and planners prior to the start of this activity by using a multistep process.

Off-Label Disclosure and Disclaimer

This activity may or may not discuss investigational, unapproved, or off-label use of drugs. Learners are advised to consult prescribing information for any products discussed. The information provided in this accredited activity is for continuing education purposes only and is not meant to substitute for the independent clinical judgment of a health care professional relative to diagnostic, treatment, or management options for a specific patient’s medical condition. The opinions expressed in the content are solely those of the individual faculty members and do not reflect those of PER® or any company that provided commercial support for this activity.